The Current Understanding of and Treatment Paradigm for Newly-Diagnosed <i>TP53</i>-Mutated Acute Myeloid Leukemia
About 10% of newly diagnosed and 20–30% of therapy-related acute myeloid leukemia (AML) harbors a <i>TP53</i> mutation (<i>mTP53</i>-AML). Unfortunately, this biological subset predicts one of the worst prognoses among patients with AML, specifically a median overall survival of about 7 months with...
Gorde:
| Egile Nagusiak: | , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
MDPI AG
2021-12-01
|
| Saila: | Hemato |
| Gaiak: | |
| Sarrera elektronikoa: | https://www.mdpi.com/2673-6357/2/4/51 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|